The anthrax toxin consists of protective antigen (PA), lethal factor (LF) and edema factor (EF). PA mediates the entry of LF and EF to the cytosol where they exert their effects. Although PA is the major component of the vaccines against anthrax, LF has also been found to play an important role in enhancing protective immunity. We have developed an osmolyte-inducible LF expression system. The protein expression system contributed no additional amino acids to the recombinant LF making it suitable for the human vaccine trials. ß
Introduction
The anthrax toxins play a key role in the pathogenesis of anthrax. A combination of protective antigen (PA) and edema factor (EF) forms edema toxin, which causes edema, and when PA combines with lethal factor (LF), lethal toxin is formed [1] . Lethal toxin causes the death of experimental animals and cytolysis of peritoneal macrophages and macrophage-like cell lines such as J774A.1 and RAW 264.7 [2] . Continuous protein synthesis and the presence of extracellular calcium is required for the expression of anthrax lethal toxin activity [3, 4] .
The currently available human anthrax vaccine consists predominantly of PA [5] . It has been suggested that in addition to PA, LF and EF also play an important role in providing protective immunity [6] . Recent studies have demonstrated that the intracellular expression of LF alone can provide complete protection against anthrax lethal toxin challenge [7] . This result supports a possible role for an anti-LF antibody response in protection against anthrax infection. In order to test the potential of LF as a vaccine candidate, large-scale pure preparation of LF is required.
Although we have expressed LF as a fusion protein in Escherichia coli, this system su¡ers from two main disadvantages [8, 9] . The ¢rst is the presence of 12 additional amino acids at the N-terminus of the recombinant LF (rLF). Six amino acids were derived from the N-terminal histidine tag (6X His) and the remaining six were added by polymerase chain reaction (PCR) manipulations. Although the His tag is poorly immunogenic, its presence in the therapeutically important proteins is not desirable. The presence of the His tag had an unexpected in£uence on the processing, kinetics and folding parameters of Llactamase enzyme [10] . Therefore, the presence of these extra amino acids may account for some side e¡ects and may limit the use of the rLF for the human vaccine trials. The second disadvantage is the use of isopropyl L-D-thiogalactopyranoside (IPTG) to achieve expression of LF. The high cost of IPTG limits the use of this system for the large-scale production of rLF. Moreover, the use of IPTG for the production of therapeutically important proteins is undesirable because of its toxicity [11] .
We have tried to overcome these problems by developing a new expression system for the production of LF. The LF gene was cloned downstream of the strong phage T7 promoter. E. coli host strain GJ1158 used for the expression studies contains a chromosomally integrated T7 RNA polymerase gene downstream of an osmotically inducible proUP promoter [12] . A combination of sucrose and sorbitol was used to induce the expression of the LF gene. The rLF was expressed as a fusion protein containing 6X His tag at its N-terminus. We have removed the 6X His tag using a speci¢c enterokinase enzyme leaving the rLF devoid of any extra amino acids. This system also has the potential of reducing the scale-up cost and simplifying downstream processing since the requirement of IPTG has been circumvented. The yield of the puri¢ed rLF was V4.0 mg l 31 . The expressed protein is biologically and functionally active.
Materials and methods

Materials
Biochemicals were purchased from USB chemicals (USA). Bacterial culture medium was purchased from Hi-Media laboratories (India). Trypsin, sorbitol, MTT (3-[4-5-dimethylthiazol-2-yl]-2-5-diphenyltetrazolium bromide) and the monoclonal antibody against the His tag were purchased from Sigma (USA). RAW 264.7, a macrophage-like cell line, was obtained from the American Type Culture Collection (USA). The expression vector pRSETA was obtained from Invitrogen (USA). Enterokinase enzyme was purchased from Novagen (USA).
Plasmid construction
The 2.3-kb fragment containing the complete LF gene was PCR-ampli¢ed using the Bacillus anthracis plasmid pXO1 as template. The forward primer 5P-GTA CAG GGA TCC CAC CAT CAC CAT CAC CAT GAC GAT GAC GAT AAG GCG GGC GGT-3P generated a BamHI restriction site and the reverse primer 5P-GAA AAT TTT TAA TAG GTA CCT TAT GAG-3P generated a KpnI restriction site in the ampli¢ed product. The PCRampli¢ed fragment was digested with the BamHI and the KpnI enzymes and cloned in the BamH1^Kpn1-digested pRSETA plasmid. The plasmid containing the LF gene was named pAS1.
Expression of LF in E. coli GJ1158
The plasmid pAS1 was transformed in the GJ1158 host strain. The presence of the plasmid was con¢rmed by minipreparations of plasmid DNA. Cells containing the plasmids were grown on LBON media (10 g l 31 Bactotryptone, 5 g l 31 yeast extract) containing 100 Wg ml 31 of ampicillin at 37 ‡C and 200 rpm. When the OD 600 (optical density at 600 nm) reached V0.8^1.0, osmotic shock was given by adding di¡erent concentrations of sodium chloride, sorbitol and sucrose. Optimal expression was achieved with 0.3 M sorbitol and 0.06 M sucrose. Therefore, the above-mentioned concentrations were used and the incubation was continued at 37 ‡C. After 2 h of induction, additional 0.1 M sorbitol was added and incubation was continued for 3 h. Samples were collected before and after induction and subjected to 12% sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and electroblotted.
Localization of expressed LF
For localizing the expressed recombinant protein in the cell, the E. coli GJ1158 strain containing the recombinant plasmid was grown and induced under the above-mentioned conditions. The cells were harvested by centrifugation at 5000Ug for 10 min. The periplasm, cytosol and inclusion body fractions were prepared. These samples were subjected to SDS^PAGE and electroblotted.
Puri¢cation of rLF and cleavage of His tag
rLF was puri¢ed by Ni-NTA chromatography according to the method previously described [8] . Protein was estimated by the method of Bradford. The estimated protein was then bound to the Ni-NTA-packed column by virtue of its 6X His sequence and the rLF was cleaved by using an enterokinase enzyme. The conditions for the e⁄cient removal of the 6X His tag were standardized. One unit of enterokinase enzyme was found to be su⁄cient for the cleavage of V45 Wg of recombinant protein and the reaction was carried out at 4 ‡C for 20 h. Elution bu¡er (50 mM Na-phosphate bu¡er pH 7.0, and 300 mM NaCl) was used to elute the recombinant protein. The eluted protein was further puri¢ed by FPLC according to the method previously described [8] . Samples were then subjected to SDS^PAGE and electroblotted.
Binding of rLF to PA in vitro
PA cleaved by trypsin has the ability to bind to LF in solution. To study the binding of rLF to proteolytically nicked PA, the PA molecule was digested with trypsin. PA (1.0 mg ml 31 ) was incubated with trypsin (1.0 ng Wg 31 of protein) for 30 min at room temperature in 25 mM HEPES, 1 mM CaCl 2 , 0.5 mM EDTA pH 7.5. Trypsin was inactivated by adding PMSF to a ¢nal concentration of 1 mM. Trypsin-nicked PA (1.0 mg ml 31 ) was incubated with rLF (1.0 mg ml 31 ) in 25 mM Tris, pH 9.0, containing 2.0 mg ml 31 3-{3-cholamidopropyl) dimethyl ammonio}-propanesulfonic acid for 15 min at room temperature. LF from B. anthracis along with PA was used as a positive control. Samples were applied to a non-denaturing 4.5% polyacrylamide gel. Gels were stained in Coomassie brilliant blue, destained and analyzed.
Cell culture and cytotoxicity assay
A macrophage-like cell line RAW 264.7 was maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum, 25 mM HEPES, 100 U ml 31 penicillin and 200 Wg ml 31 streptomycin. rLF was added in varying concentrations with PA (1.0 Wg ml 31 ) and incubated for 3 h at 37 ‡C. LF from B. anthracis along with PA was used as a positive control. Cell viability was determined by MTT dye in which MTT dissolved in RPMI 1640 medium was added to each well at a ¢nal concentration of 0.5 mg ml 31 . Cells were incubated for another 45 min at 37 ‡C to allow uptake and oxidation of dye by viable cells. The medium was replaced by 0.5% (w/v) SDS, 25 mM HCl in 90% isopropyl alcohol, the plate was vortexed and the OD was read at 540 nm.
Results and discussion
E. coli is a widely used host strain for the high level production of recombinant proteins [13] . The bacteriophage T7 promoter-based system where T7 RNA polymerase is under the control of the lac promoter is one of the strongest expression systems in E. coli [14] . Di¡erent induction strategies have been used to achieve the recombinant protein synthesis under the control of T7 promoter. These include the use of IPTG to induce the lac promoter and its variants or by heat induction of a phage V promoter. The use of IPTG for the production of therapeutically important proteins is undesirable because of its toxicity [11] . In addition, IPTG induction increases the cost of production during scale-up. For heat induction, ensuring a rapid temperature up-shift is di⁄cult while handling larger culture volumes. Also inclusion body formation and the induction of several proteases upon heat shock a¡ect the ¢nal product concentration and purity [15] . E. coli GJ1158 host containing a chromosomally integrated T7 RNA polymerase gene downstream of an osmotically inducible proUP promoter addresses most of the problems associated with protein expression [12] . In this system any target gene cloned downstream of the T7 promoter and introduced into E. coli GJ1158 host strain can be overexpressed by salt/osmolyte induction [12, 16] . However, each gene presents unique challenges for its overproduction and regulatory elements have to be individually optimized in each instance.
In this study we have overexpressed the LF gene of B. anthracis using osmolyte induction. To check the expression of the recombinant protein, uninduced and induced samples were subjected to SDS^PAGE and electroblotted. Developing the blot with anti-LF antibodies con¢rmed the presence of the recombinant protein (Fig. 1A,B) . Optimal expression was achieved with 0.3 M sorbitol and 0.06 M sucrose. In order to maintain the osmotic pressure sorbitol was added in two stages, 0.3 M initially and an additional 0.1 M after 2 h of induction. Sorbitol probably also acted as an additional carbon source and therefore the exponential phase of the culture was extended. Since protein production is growth-associated, keeping the cells in the exponential phase results in higher expression levels [17] . Sucrose is not metabolized by E. coli but it was added along with sorbitol into the culture medium to achieve better expression by enhancing the osmotic pressure. The expressed protein was localized in the cytosol (data not shown).
The expression of LF with a 6X His tag allowed for the convenient puri¢cation of the fusion protein from other soluble bacterial proteins. The recombinant protein was puri¢ed by Ni-NTA a⁄nity chromatography. It was then subjected to enterokinase reaction to remove the Nterminal 6X His tag. The protein was further puri¢ed by FPLC (Fig. 1A,B) . More than 95% pure protein was obtained. The rLF was puri¢ed with 3603-fold puri¢cation compared to the cytosolic fraction (Table 1) . Puri¢ed fractions were subjected to SDS^PAGE and electroblotted. When the blot was developed with anti-His antibody, no bands were seen. This shows that the tag sequence had been completely removed from the fusion protein and that the cleaved tag had not coeluted from the Ni-NTA column with the rLF (Fig. 2A) . Developing the blot with anti-LF antibody gave bands corresponding to LF ensuring that there was no degradation of rLF during enterokinase reaction (Fig. 2B) . Also, there was no residual enterokinase activity in the FPLC-puri¢ed fractions (data not shown).
The puri¢ed protein was then assayed for its in vitro binding to trypsin-nicked PA. Both rLF and LF from B. anthracis were incubated with trypsin-nicked PA. PA^LF binding was analyzed on a 4.5% polyacrylamide gel. It was observed that the rLF-like LF from B. anthracis was capable of binding to PA to form a PA^LF complex (Fig. 3) . The rLF was also assayed for its biological activity by performing a cytotoxicity assay on RAW 264.7 cells. rLF and LF from B. anthracis were added to the cells at concentrations ranging from 0.01 to 1 Wg ml 31 in combination with PA (1 Wg ml 31 ). After 3 h of incubation, the cell viability was determined by adding MTT dye. Live cells oxidized the dye to formazon crystals. The precipitate was solubilized and the OD was read at 540 nm. It was observed that the rLF along with PA was fully able to lyse the cells and its biological activity was similar to LF from B. anthracis (Fig. 4) . The EC 50 of the rLF was found to be V0.05 Wg ml 31 . Thus, puri¢ed preparation of LF was obtained after a⁄nity chromatography and FPLC. 4.0 mg l 31 of rLF could be obtained from 1 l of culture. The recombinant protein was biologically and functionally active as compared to the native LF from B. anthracis. The present work would make the large-scale production of rLF cost-e¡ective and simple. We are trying to scale-up the expression of rLF by bioprocess optimization. The availability of large amounts of LF should not only facilitate LF-based vaccine trials but also aid basic research. Fig. 4 . Biological activity of LF puri¢ed from E. coli GJ1158. RAW 264.7 cells were incubated with varying concentrations of rLF in combination with PA (1.0 Wg ml 31 ) for 3 h at 37 ‡C. At the end of the experiment cytotoxicity was determined by MTT assay. The OD obtained at 540 nm (1.202) with untreated cells was considered 100% viability.
